Literature DB >> 30900136

Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis.

Weihua Chen1, Yiran Wei1, Aizhen Xiong2, Yanmei Li1, Huida Guan2, Qixia Wang1, Qi Miao1, Zhaolian Bian3, Xiao Xiao1, Min Lian1, Jun Zhang1, Bo Li1, Qin Cao4, Zhuping Fan4, Weici Zhang5, Dekai Qiu1, Jingyuan Fang1, M Eric Gershwin5, Li Yang6, Ruqi Tang7, Xiong Ma8.   

Abstract

Accumulation of bile acids (BAs) contributes significantly to the pathogenesis of primary biliary cholangitis (PBC). Here, we sought to systematically characterize the serum and fecal BA profiles and the linkage between BAs and gut microbiota in PBC. The serum and fecal BAs were compared between 65 UDCA treatment-naive PBC and 109 healthy controls using UPLC-MS in cross-sectional study. In a prospective study, a subgroup of patients was enrolled for BA and microbiota analysis before and after UDCA therapy. BA compositions in serum and feces significantly differed between treatment-naive PBC and controls. Particularly, PBC was associated with decreased conversions of conjugated to unconjugated, and primary to secondary BAs, indicating impaired microbial metabolism of BAs. PBC patients at advanced stage exhibited a more abnormal BA profile compared with early-stage patients. UDCA treatment led to a decreased level of taurine-conjugated BAs, thereby reversing the conjugated/unconjugated ratio in PBC. Moreover, the level of secondary BAs such as DCA and conjugated DCA inversely correlated with PBC-enriched gut microbes (e.g., Veillonella, Klebsiella), while positively correlated with control-enriched microbes (e.g., Faecalibacterium, Oscillospira). Microbiota analysis also revealed a significant increase of taurine-metabolizing bacteria Bilophila spp. in patients after UDCA, which was strongly correlated with decreased taurine-conjugated BAs. In addition, serum FGF19 was remarkably increased in treatment-naïve PBC and decreased after UDCA. Our study established specific alterations of BA compositions in serum and feces of PBC, suggesting the potential for using BAs for diagnosis, and highlighting the possibility of modulating BA profile by altering gut microbiota. Graphical Abstract.

Entities:  

Keywords:  Bile acids; Gut microbiota; Primary biliary cholangitis; Ursodeoxycholic acid

Year:  2020        PMID: 30900136     DOI: 10.1007/s12016-019-08731-2

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  31 in total

1.  Alterations in microbiota and their metabolites are associated with beneficial effects of bile acid sequestrant on icteric primary biliary Cholangitis.

Authors:  Bo Li; Jun Zhang; Yong Chen; Qixia Wang; Li Yan; Rui Wang; Yiran Wei; Zhengrui You; Yikang Li; Qi Miao; Xiao Xiao; Min Lian; Weihua Chen; Dekai Qiu; Jingyuan Fang; M Eric Gershwin; Ruqi Tang; Xiong Ma
Journal:  Gut Microbes       Date:  2021 Jan-Dec

2.  Gut microbiome in liver pathophysiology and cholestatic liver disease.

Authors:  Shengmin Yan; Xiao-Ming Yin
Journal:  Liver Res       Date:  2021-08-08

Review 3.  The intestinal and biliary microbiome in autoimmune liver disease-current evidence and concepts.

Authors:  Timur Liwinski; Melina Heinemann; Christoph Schramm
Journal:  Semin Immunopathol       Date:  2022-05-10       Impact factor: 11.759

4.  Multi-omics: Differential expression of IFN-γ results in distinctive mechanistic features linking chronic inflammation, gut dysbiosis, and autoimmune diseases.

Authors:  Heekyong R Bae; Patrick S C Leung; Deborah L Hodge; John M Fenimore; Seon-Min Jeon; Vishal Thovarai; Amiran Dzutsev; Andrew A Welcher; Michael Boedigheimer; Michael A Damore; Myung-Sook Choi; Richard A Fravell; Giorgio Trinchieri; M Eric Gershwin; Howard A Young
Journal:  J Autoimmun       Date:  2020-03-24       Impact factor: 7.094

5.  Short-chain fatty acid and fecal microbiota profiles are linked to fibrosis in primary biliary cholangitis.

Authors:  Craig Lammert; Andrea S Shin; Huiping Xu; Christopher Hemmerich; Thomas M O'Connell; Naga Chalasani
Journal:  FEMS Microbiol Lett       Date:  2021-04-22       Impact factor: 2.742

Review 6.  Gut microbiome, liver immunology, and liver diseases.

Authors:  Rui Wang; Ruqi Tang; Bo Li; Xiong Ma; Bernd Schnabl; Herbert Tilg
Journal:  Cell Mol Immunol       Date:  2020-12-14       Impact factor: 11.530

Review 7.  A Current Understanding of Bile Acids in Chronic Liver Disease.

Authors:  Naba Farooqui; Anshuman Elhence
Journal:  J Clin Exp Hepatol       Date:  2021-08-23

8.  Changes in the gut microbiota of mice orally exposed to methylimidazolium ionic liquids.

Authors:  Gregory R Young; Tarek M Abdelghany; Alistair C Leitch; Michael P Dunn; Peter G Blain; Clare Lanyon; Matthew C Wright
Journal:  PLoS One       Date:  2020-03-12       Impact factor: 3.240

9.  Hepatic Vps33b deficiency aggravates cholic acid-induced cholestatic liver injury in male mice.

Authors:  Kai-Li Fu; Pan Chen; Yan-Ying Zhou; Yi-Ming Jiang; Yue Gao; Hui-Zhen Zhang; Li-Huan Guan; Cong-Hui Wang; Jun-Ling Liu; Min Huang; Hui-Chang Bi
Journal:  Acta Pharmacol Sin       Date:  2021-07-12       Impact factor: 6.150

Review 10.  Fibrotic Events in the Progression of Cholestatic Liver Disease.

Authors:  Hanghang Wu; Chaobo Chen; Siham Ziani; Leonard J Nelson; Matías A Ávila; Yulia A Nevzorova; Francisco Javier Cubero
Journal:  Cells       Date:  2021-05-05       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.